2004年10月
Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors.
Drug metabolism and pharmacokinetics
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 19
- 号
- 5
- 開始ページ
- 375
- 終了ページ
- 80
- 記述言語
- 英語
- 掲載種別
- Scientific Journal
- DOI
- 10.2133/dmpk.19.375
The effect of genetic polymorphism of human organic anion transporting polypeptide C (OATP-C) on the lipid-lowering response to 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors was assessed. A retrospective study was conducted on 66 patients who underwent treatment of hyperlipidemia with HMG-CoA reductase inhibitors in a municipal hospital in a community-based cohort of Ehime prefecture in the southern part of Japan. Plasma lipid concentrations before and after administration were analyzed in patients in relation to the 521T/C (Val-174-->Ala) polymorphism in the OATP-C gene (TT: n=44 (66.7%), TC: n=20 (30.3%), CC: n=0 (0.0%), undetermined: n=2 (3.0%)). Total cholesterol level was significantly lowered after treatment with HMG-CoA reductase inhibitors in all patients (p<0.001); moreover, subjects with the 521C allele showed an attenuated total-cholesterol-lowering effect compared with those homozygous for the 521T allele (-22.3+/-8.7% vs. -16.5+/-10.5%, p<0.05). These data suggest that the 521T/C polymorphism of the OATP-C gene modulates the lipid-lowering efficacy of HMG-CoA reductase inhibitors.
- リンク情報
- ID情報
-
- DOI : 10.2133/dmpk.19.375
- ISSN : 1347-4367
- CiNii Articles ID : 10014314699
- PubMed ID : 15548849